Intravenous ω-3 Fatty Acids Plus Gemcitabine
| Autor: | Christopher D. Mann, Franscois Runau, John Isherwood, Matthew S. Metcalfe, William P. Steward, Ali Arshad, Ashley R. Dennison, Cristina Pollard, Bruno Morgan, Jill Cooke |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Response rate (survey) medicine.medical_specialty Nutrition and Dietetics business.industry Medicine (miscellaneous) Cancer medicine.disease Gemcitabine 03 medical and health sciences 0302 clinical medicine Endocrinology Quality of life 030220 oncology & carcinogenesis Internal medicine Pancreatic cancer Toxicity medicine 030212 general & internal medicine Progression-free survival business Adverse effect medicine.drug |
| Zdroj: | Journal of Parenteral and Enteral Nutrition. 41:398-403 |
| ISSN: | 1941-2444 0148-6071 |
| DOI: | 10.1177/0148607115595221 |
| Popis: | Background: Marine-derived ω-3 fatty acids (ω-3FAs) have proven antitumor activity in vivo and in vitro and improve quality of life (QOL) in clinical cancer studies. These changes may be mediated by reduction in circulating proangiogenic and proinflammatory factors. In this first study of intravenous ω-3FAs as a therapy in cancer patients, we aimed to assess if it could augment the antitumor activity of gemcitabine in patients with advanced pancreatic cancer and improve QOL. Materials and Methods: Patients were administered gemcitabine 1000 mg/m3 weekly followed by up to 100 g (200 mg/mL) of ω-3 rich lipid emulsion for 3 weeks followed by a rest week. This was continued for up to 6 cycles, progression, unacceptable toxicity, patient request, or death. The primary outcome measure was objective response rate, with secondary outcome measures of overall and progression free survival, QOL scores, and adverse events. Results: Fifty patients were recruited. Response rate was 14.3% and disease control rate was 85... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text